摘要
目的探讨甲地孕酮联合化疗治疗晚期恶性肿瘤患者的临床效果。方法选取2014年4月~2015年6月我院收治的86例恶性肿瘤患者,86例患者先接受1周期的单独化疗,在第2周期化疗开始前2d持续应用甲地孕酮14 d,观察2个周期患者的主要营养指标以及不良反应发生情况。结果第2周期患者的KPS评分明显高于第1周期,体重明显增加,血清蛋白和血清前白蛋白较第1周期有明显改善,恶心、呕吐等不良反应明显改善,但是血红蛋白无明显差异。结论甲地孕酮联合化疗治疗晚期恶性肿瘤能够明显提高患者治疗期间的多项营养指标,改善患者的生活质量,削弱化疗对人体的损害,增强患者对化疗的耐受性和顺应性,该方法安全可靠。
Objective To assess the value of megestrol acetate in advanced cancer when given around thechemotherapy. Methods 86 cases of malignant tumor patients were selected from April 2014 to June 2015 in our hospital, 86 patients received chemotherapy alone in the first cycle and combined megestrol acetate in the second cycle. Megestrol acetate was prescribed for 14 d and taken two days before the second cycle. Nutrition indices and symptoms of nausea/vomiting during the two different cyclesrecorded and analyzed. Results KPS score in the second cycle patients was significantly higher than that in the first cycle, body weight increased significantly, serum protein and serum albumin was the first cycle have significantly improved, but hemoglobin were significantly different, nausea, vomiting and other adverse reactions without significantly improved. Conclusion Megestrol acetate can effectively improve the condition of nutrition and enhance adaptability and tolerance for chemotherapy in advanced cancer patients with good safety.
出处
《中国继续医学教育》
2016年第7期141-142,共2页
China Continuing Medical Education
